{"entity":{"id":"nct02739594","kind":"trial","name":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma","aka":[],"tldr":"A phase 3 trial of Ibandronic acid and Zoledronic acid in Multiple myeloma, run by Hoffmann-La Roche, recorded as terminated on the registry.","summary":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma is a phase 3 interventional study registered as NCT02739594 by Hoffmann-La Roche, with 89 participants recorded, started 2006-02 and due to reach its primary completion in 2009-04. Interventions recorded: Ibandronate, Zoledronate. Conditions recorded: Multiple Myeloma.\n\nLinked to the drug Ibandronic acid because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02739594","url":"https://clinicaltrials.gov/study/NCT02739594"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["ibandronic-acid","zoledronic-acid"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02739594","phase":"3","setting":"COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma","sponsor":"Hoffmann-La Roche","enrolled":89,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02739594/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"ibandronic-acid","kind":"drug","name":"Ibandronic acid","route":"/drugs/ibandronic-acid/"},{"id":"zoledronic-acid","kind":"drug","name":"Zoledronic acid","route":"/drugs/zoledronic-acid/"}]}}